

Reference Data

1st Quarter - Fiscal Year 2021
(April 1, 2021 to June 30, 2021)

Consolidated Earnings

- Consolidated Financial Data p. 1
- Consolidated Balance Sheets p. 2
- Consolidated P/L Statement p. 3
- Consolidated Sales Breakdown by Segment/Category p. 4
- Consolidated Operating Profit by Segment p. 4
- Consolidated Sales -
 - Leading Brands of Self-Medication Operations
 - Sales by Region p. 5
- Consolidated Sales -
 - Leading Products of Prescription Pharmaceutical Operations p. 6
- Capital Expenditure p. 7
- Depreciation and Amortization p. 7
- R&D Expenses p. 7
- Results of Major Consolidated Subsidiary
 - ♦ Taisho Pharmaceutical p. 8
- Major Subsidiaries and Affiliates p. 9
- Prescription Pharmaceutical Operations:
 - New Drug Development-Taisho Pharmaceutical p. 10
- Launch of New Products p. 12

Taisho Pharmaceutical Holdings Co.,Ltd.

Consolidated Financial Data

(Millions of yen)

	March 2021(FY2020)				March 2022(FY2021)***			
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q(4-6) Before deduction of sales	1Q (4-6)	Full year E Before deduction of sales	Full year E
Net sales	75,023	145,900	214,300	281,980	66,609	63,884	284,000	269,000
(YOY%)	(+24.5%)	(+10.4%)	(+1.4%)	(-2.3%)	(-11.2%)	(-14.8%)	(+0.7%)	(-4.6%)
Self-Medication operations	56,436	113,657	169,177	226,878	55,551	53,623	242,900	231,100
Prescription Pharmaceutical operations	18,587	32,243	45,123	55,101	11,057	10,260	41,100	37,900
Gross profit on sales*	47,228	93,575	136,669	175,986	42,282	39,739	179,200	165,500
Selling, general and administrative expenses	37,838	77,279	115,805	156,021	39,871	37,063	164,700	151,000
Research and development expenses	4,209	9,429	14,354	20,251	4,629	4,629	21,600	21,600
(% Sales)	(5.6%)	(6.5%)	(6.7%)	(7.2%)	(7.0%)	(7.2%)	(7.6%)	(8.0%)
Advertising expenses	6,107	11,905	17,645	25,017	7,029	7,029	32,000	32,000
Sales promotion expenses	5,827	12,404	18,875	24,527	5,568	3,421	23,300	13,100
Personnel expenses	8,201	16,522	25,039	32,953	9,701	9,701	33,100	33,100
Operating Profit	9,389	16,295	20,864	19,965	2,411	2,676	14,500	14,500
(YOY%)	(+12.8%)	(+12.2%)	(+22.1%)	(-5.5%)	(-74.3%)	(-71.5%)	(-27.4%)	(-27.4%)
Earnings before the amortization of goodwill and trademarks	12,399	22,233	29,839	32,008	5,491	5,756	26,400	26,400
Ordinary Profit	11,117	18,859	24,742	25,946	3,768	4,033	18,500	18,500
(YOY%)	(+45.3%)	(+29.1%)	(+22.0%)	(+6.0%)	(-66.1%)	(-63.7%)	(-28.7%)	(-28.7%)
Profit attributable to owners of parent	6,064	11,294	14,235	13,316		1,179	10,500	10,500
(YOY%)	(-44.9%)	(-23.6%)	(-20.0%)	(-34.0%)		(-80.5%)	(-21.1%)	(-21.1%)
Comprehensive income	3,537	10,802	16,541	28,920		6,953	-	-
(YOY%)	(-33.3%)	(+36.4%)	(+88.0%)	(+241.4%)		(+96.6%)	-	-
Basic EPS (yen)	75.98	141.51	178.35	166.84		14.78	131.45	131.45
Diluted EPS (yen)	75.89	141.34	178.12	166.63		14.75	131.29	131.29
BPS (yen)	8,862.95	8,949.88	8,967.90	9,129.95		9,131.84	9,158.01	9,158.01
Dividend per share (yen)	-	50.00	-	100.00		-	100.00	100.00
Payout ratio	-	-	-	59.9%		-	76.1%	76.1%
Capital expenditure	2,659	5,701	8,182	15,121		1,779	17,600	17,600
Depreciation and amortization	3,673	7,206	10,925	14,700		3,508	14,000	14,000
Total assets	858,187	861,043	861,329	876,923		877,471	879,000	879,000
Shareholders' equity	736,944	744,157	745,217	758,406		757,842	761,000	761,000
Return on equity (%)**	-	-	-	1.9%		-	1.4%	1.4%
Return on assets (%)**	-	-	-	1.5%		-	1.2%	1.2%
Equity ratio (%)	82.4%	83.0%	83.1%	83.1%		83.1%	83.2%	83.2%
Overseas sales	27,063	47,518	67,833	92,607	24,865	24,824	98,400	98,400
Overseas sales ratio (% of total sales)	36.1%	32.6%	31.7%	32.8%	37.3%	38.9%	34.6%	36.6%
Number of employees	9,356	9,304	9,234	9,195		9,254	-	-

* After provision/reversal of reserve for returned unsold goods

** Average of the beginning and year-end balance of shareholders' equity / total assets

*** The accounting standard for revenue recognition has been applied from FY2021 onwards.

<Reference>

• E = Estimates

• Full year forecasts for the fiscal year ending March 31, 2022 were announced on May 14, 2021.

Consolidated Balance Sheets

(Millions of yen)

(Millions of yen)

	End of FY2020		End of FY2021 1Q*		change	
	(March 31, 21)	% total	(June 30, 21)	% total		
(Assets)						
I Current assets:	357,731	40.8%	358,656	40.9%	+925	
Cash and deposits	250,178		249,615		-562	
Notes and accounts receivable-trade	51,609		49,286		-2,323	
Marketable securities	4,017		4,017		-0	
Inventories	46,384		46,702		+317	
Other	5,540		9,035		+3,494	
II Fixed assets:	519,192	59.2%	518,814	59.1%	-377	
(1) Tangible fixed assets:	113,194	(12.9%)	112,653	(12.8%)	-540	
Buildings and structures	51,876		51,508		-368	
Machinery, equipment and vehicles	14,494		14,423		-71	
Land	37,429		37,453		+24	
Other	9,393		9,268		-125	
(2) Intangible fixed assets:	216,532	(24.7%)	220,753	(25.2%)	+4,220	
Goodwill	128,612		130,206		+1,594	Change of the rate of exchange
Sales rights	453		431		-21	
Trademarks	69,258		70,428		+1,170	Change of the rate of exchange
Software	10,341		11,490		+1,148	
Other	7,867		8,195		+328	
(3) Investments and other assets:	189,464	(21.6%)	185,407	(21.1%)	-4,056	
Investment securities	156,055		152,360		-3,694	Change of stock price
Shares of subsidiaries and affiliates	12,261		12,188		-72	
Net defined benefit assets	10,620		10,762		+141	
Deferred tax assets	8,892		8,519		-372	
Other	1,634		1,576		-58	
Total assets	876,923	100.0%	877,471	100.0%	+548	
(Liabilities)						
I Current liabilities:	57,666	6.6%	59,204	6.7%	+1,537	
Notes and accounts payable-trade	14,672		12,457		-2,214	
Accounts payable	16,068		16,255		+186	
Accrued income taxes	3,275		2,190		-1,084	
Refund liability	-		6,640		+6,640	Application of the accounting standard for revenue recognition
Provision for bonuses	3,523		2,966		-557	
Other	20,126		18,693		-1,433	
II Long-term liabilities:	60,849	6.9%	60,424	6.9%	-424	
Net defined benefit liabilities	21,321		21,476		+154	
Deferred taxes liabilities	32,747		31,866		-881	
Other	6,780		7,082		+301	
Total liabilities	118,516	13.5%	119,628	13.6%	+1,112	
(Net assets)						
I Shareholders' equity	697,598	79.6%	693,644	79.1%	-3,954	
Common stock	30,000		30,000		-	
Capital surplus	12		22		+9	
Retained earnings	703,036		699,057		-3,978	Payment of dividend
Treasury stock	-35,450		-35,435		+14	
II Accumulated other comprehensive income	31,105	3.5%	35,230	4.0%	+4,124	
Valuation difference on securities	30,026		27,328		-2,697	Change of stock price
Foreign currency translation adjustment	-235		6,611		+6,847	Change of the rate of exchange
Remeasurements of defined benefit plans	1,315		1,290		-24	
III Share acquisition rights	801	0.0%	766	0.1%	-34	
IV Non-controlling interests	28,900	3.3%	28,200	3.2%	-700	
Total net assets	758,406	86.5%	757,842	86.4%	-564	
Total liabilities and net assets	876,923	100.0%	877,471	100.0%	+548	

* The accounting standard for revenue recognition has been applied from FY2021 onwards.

Consolidated P/L Statement

(Millions of yen)

	FY2020		FY2021*		YOY change	
	1Q	% total	1Q	% total		
Net sales	75,023	100.0%	63,884	100.0%	-11,139	
Cost of sales	27,837	37.1%	24,144	37.8%	-3,693	
Gross profit on sales	47,185	62.9%	39,739	62.2%	-7,445	
Provision for sales returns	-42		-		+42	
Gross profit	47,228	63.0%	39,739	62.2%	-7,488	
Selling, general and administrative expenses	37,838	50.4%	37,063	58.0%	-775	
Research and development expenses	4,209		4,629		+420	
Advertising expenses	6,107		7,029		+922	
Sales promotion expenses	5,827		3,421		-2,406	FY2021: Application of the accounting standard for revenue recognition -2,146
Personnel expenses	8,201		9,701		+1,499	
Other	13,492		12,280		-1,212	
Operating Profit	9,389	12.5%	2,676	4.2%	-6,712	
Non-operating income	1,810	2.4%	1,625	2.5%	-184	
Non-operating expenses	82	0.1%	268	0.4%	+185	
Ordinary Profit	11,117	14.8%	4,033	6.3%	-7,083	
Extraordinary income	1	0.0%	3	0.0%	+1	
Extraordinary losses	300	0.4%	32	0.1%	-267	
Profit before income taxes and minority interests	10,818	14.4%	4,004	6.3%	-6,813	
Income taxes	4,130	5.5%	2,301	3.6%	-1,829	
Profit	6,688	8.9%	1,703	2.7%	-4,984	
Profit attributable to non-controlling interests	623	0.8%	524	0.8%	-99	
Profit attributable to owners of parent	6,064	8.1%	1,179	1.8%	-4,884	

* The accounting standard for revenue recognition has been applied from FY2021 onwards.

Consolidated Sales Breakdown by Segment/Category

(Millions of yen)

	March 2021(FY2020)				March 2022(FY2021)*			
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q(4-6) Before deduction of sales	1Q (4-6)	Full year E Before deduction of sales	Full year E
Self-Medication operations	56,436	113,657	169,177	226,878	55,551	53,623	242,900	231,100
(YOY%)	(+31.4%)	(+16.6%)	(+7.2%)	(+3.1%)	(-1.6%)	(-5.0%)	(+7.1%)	(+1.9%)
Japan	28,772	64,584	98,806	130,892	30,595	28,873	141,600	131,300
Overseas	26,953	47,409	67,724	92,490	24,312	24,270	98,000	98,000
Other	710	1,663	2,646	3,495	643	479	3,300	1,800
Prescription Pharmaceutical operations	18,587	32,243	45,123	55,101	11,057	10,260	41,100	37,900
(YOY%)	(+7.3%)	(-7.1%)	(-15.7%)	(-19.6%)	(-40.5%)	(-44.8%)	(-25.4%)	(-31.2%)
Ethical drugs	18,194	31,691	44,300	54,203	10,277	9,480	40,000	36,800
Other	392	551	823	898	780	780	1,100	1,100
Total	75,023	145,900	214,300	281,980	66,609	63,884	284,000	269,000

* The accounting standard for revenue recognition applies from FY2021 onwards.

Consolidated Operating Profit by Segment

(Millions of yen)

	March 2021(FY2020)				March 2022(FY2021)*	
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	Full year E
Self-Medication operations	5,483	12,526	16,855	19,395	3,112	20,500
(YOY%)	(-22.0%)	(-2.9%)	(+23.6%)	(+3.7%)	(-43.2%)	(+5.7%)
Earnings before the amortization of goodwill and trademarks	8,494	18,464	25,830	31,438	6,192	32,400
Prescription Pharmaceutical operations (YOY%)	4,466	4,857	5,496	2,495	15	-4,000
	(+178.1%)	(+104.0%)	(+15.9%)	(-39.8%)	(-99.7%)	(-)
Other*	-561	-1,087	-1,488	-1,925	-451	-2,000
(YOY%)	(-)	(-)	(-)	(-)	(-)	(-)
Total	9,389	16,295	20,864	19,965	2,676	14,500

* The "Other" segment represents the Company (a pure holding company), which is not attributable to any reportable segment.

** The accounting standard for revenue recognition has been applied from FY2021 onwards.

Consolidated Sales - Leading Brands of Self-Medication Operations & Sales by Region

(Billions of Yen)

	March 2021(FY2020)				March 2022(FY2021)*			
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	YOY	Full year E	YOY
Japan	28.8	64.6	98.8	130.9	28.9	+0.4%	131.3	+0.3%
<i>Lipovitan</i> series	10.4	24.4	35.9	45.8	11.8	+14.0%	49.0	+6.9%
<i>Pabron</i> series	3.5	9.1	15.6	21.1	3.5	-0.3%	22.0	+4.1%
<i>RiUP</i> series	3.5	7.6	11.7	14.9	3.5	+1.3%	15.3	+2.9%
<i>Biofermin</i> series	2.4	4.9	7.4	9.8	2.5	+5.3%	10.3	+5.9%
<i>NARON</i> series	0.8	1.6	2.2	3.0	0.9	+16.4%	3.5	+14.8%
GI treatment series	0.8	1.6	2.5	3.4	0.8	+1.7%	3.5	+3.0%
<i>VICKS</i> series	0.5	1.4	2.5	3.1	0.5	-6.5%	3.5	+11.4%
<i>Livita</i> series	0.8	1.5	2.4	3.2	0.8	+1.0%	3.2	+0.7%
<i>Colac</i> series	0.8	1.5	2.4	3.1	0.7	-3.4%	3.1	-1.9%
Overseas	27.0	47.4	67.7	92.5	24.3	-10.0%	98.0	+6.0%
Asia	11.5	19.6	29.2	41.6	12.0	+4.7%	46.1	+10.8%
Europe and America	15.0	27.2	37.6	49.7	12.1	-19.3%	50.9	+2.5%
Others	0.7	1.7	2.6	3.5	0.5	-32.6%	1.8	-48.5%

(Rounded to the nearest hundred-million)

* The sales by major brands reflects the figures before application of the accounting standard for revenue recognition.

Lipovitan Series: Sales Breakdown

(Billions of Yen)

	March 2021(FY2020)				March 2022(FY2021)*			
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	YOY	Full year E	YOY
Lipovitan series	10.4	24.4	35.9	45.8	11.8	+14.0%	49.0	+6.9%
Lipovitan D	6.9	15.9	23.0	28.7	7.3	+5.9%	29.9	+4.1%
Others	3.5	8.5	12.8	17.1	4.5	+29.9%	19.1	+11.6%

(Rounded to the nearest hundred-million)

* The sales by major brands reflects the figures before application of the accounting standard for revenue recognition.

Consolidated Sales - Leading Brands of Prescription Pharmaceutical Operations

(Billions of Yen)

	March 2021(FY2020)				March 2022(FY2021)*			
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	YOY	Full year E	YOY
Lusefi	2.6	5.2	8.3	10.8	3.1	+18.4%	14.0	+29.6%
Bonviva	1.7	3.4	5.3	6.9	1.8	+8.9%	7.1	+3.1%
LOQOA	0.9	1.9	3.0	3.8	1.0	+1.9%	4.5	+18.2%
Biofermin	1.1	1.8	2.5	3.4	1.1	+2.7%	4.5	+32.4%
Clarith	0.5	1.0	1.8	2.2	0.5	-1.6%	1.9	-13.1%
Palux	0.6	1.2	1.9	2.4	0.6	-7.3%	1.9	-20.2%
Geninax	1.8	2.2	2.2	2.2	-	-	1.0	-54.6%

(Rounded to the nearest hundred-million)

* The sales by major brands reflects the figures before application of the accounting standard for revenue recognition.

Consolidated: Capital Expenditure

(Millions of yen)

	March 2021(FY2020)				March 2022(FY2021)	
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	Full year E
Total capital expenditure	2,659	5,701	8,182	15,121	1,779	17,600
Taisho Pharmaceutical	1,081	3,258	5,170	7,793	1,316	10,350
Production department	358	652	904	1,379	269	1,210
Research department	37	764	1,013	1,519	8	5,540
Head Office and the others	684	1,841	3,252	4,894	1,039	3,600
Other subsidiaries	1,578	2,443	3,012	7,327	462	7,250

Consolidated: Depreciation and Amortization

(Millions of yen)

	March 2021(FY2020)				March 2022(FY2021)	
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	Full year E
Depreciation and amortization	3,673	7,206	10,925	14,700	3,508	14,000
Cost of sales	1,393	2,687	4,082	5,278	1,280	4,700
SGA expenses	2,280	4,519	6,843	9,421	2,228	9,300

Consolidated: R&D Expenses

(Millions of yen)

	March 2021(FY2020)				March 2022(FY2021)	
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	Full year E
Total R&D expenses	4,209	9,429	14,354	20,251	4,629	21,600
Self-Medication operations	1,578	3,469	5,374	7,492	1,952	7,900
Prescription Pharmaceutical operations	2,630	5,960	8,980	12,758	2,677	13,700

Result of Major Consolidated Subsidiary

Sales and earnings of Taisho Pharmaceutical

(Billions of Yen)

	March 2021(FY2020)				March 2022(FY2021)*	
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	YOY
Net Sales	48.9	98.7	146.9	190.2	40.3	-17.5%
Self-Medication	30.3	66.5	101.9	135.2	30.1	-0.8%
Prescription Pharmaceutical	18.6	32.2	45.0	55.0	10.2	-44.9%
Operating profit	5.7	10.3	14.8	16.5	1.4	-75.2%
Ordinary profit	11.7	17.6	24.4	27.8	5.1	-56.3%
Profit	9.4	13.8	18.9	18.5	4.1	-56.2%

(Rounded to the nearest hundred-million)

* The accounting standard for revenue recognition has been applied from FY2021 onwards.

Major Subsidiaries and Affiliates

(As of June 30, 2021)

Company	Address	Capital	Business	Ownership*
(1) Consolidated subsidiaries				%
Taisho Pharmaceutical Co., Ltd.	Tokyo, Japan	,000 Yen 29,837,892	SMG PD	100.0
MEJIRO KOSAN Co., Ltd.	Tokyo, Japan	,000 Yen 600,000	SMG	100.0
Taisho Okinawa Co., Ltd.	Okinawa, Japan	,000 Yen 50,000	SMG	100.0
Taisho M.T.C. Co., Ltd.	Tokyo, Japan	,000 Yen 400,000	SMG	60.0
Taisho Pharmaceutical Logistics Co., Ltd.	Saitama, Japan	,000 Yen 30,000	SMG	100.0
Biofermin Pharmaceutical Co., Ltd.	Hyogo, Japan	,000 Yen 1,227,000	SMG PD	63.9**
Taisho Pharma Co., Ltd.	Tokyo, Japan	,000 Yen 100,000	PD	100.0
TAISHO ACTIVE HEALTH Co., Ltd.	Tokyo, Japan	,000 Yen 100,000	SMG	55.0
TOKUHON Corporation	Tokyo, Japan	,000 Yen 300,000	SMG PD	100.0
Dr. Program Co., Ltd.	Tokyo, Japan	,000 Yen 251,500	SMG	100.0
Taisho Pharmaceutical (Taiwan) Co., Ltd.	Taiwan	,000 NT\$ 200,000	SMG	100.0
Taisho Pharmaceutical California Inc.	U.S.A.	,000 US\$ 41,050	SMG	100.0
Taisho Pharmaceuticals (Philippines), Inc.	Philippines	,000 Peso 18,900	SMG	100.0
Taisho Co., Ltd. Shanghai	China	,000 CNY 132,621	SMG	100.0
Taisho Vietnam Co., Ltd.	Vietnam	,000 VND 170,754,300	SMG	100.0
Taisho Pharmaceutical (H.K.) Ltd.	China	,000 HK\$ 10,000	SMG	100.0
Osotspa Taisho Pharmaceutical Co., Ltd.	Thailand	,000 THB 100,000	SMG	60.0
Taisho Pharmaceutical R&D Inc.	U.S.A.	,000 US\$ 4,000	PD	100.0
PT. Taisho Pharmaceutical Indonesia Tbk	Indonesia	,000 rupiah 10,240,000	SMG	98.6
Taisho Pharmaceutical Singapore Private Limited	Singapore	,000 US\$ 1,365	SMG	100.0
Hoepharm Holdings Sdn.Bhd.	Malaysia	,000 MYR 32,380	SMG	100.0
Compañía Internacional de Comercio, S.A.P.I. de C.V.	Mexico	,000 MXN 122,467	SMG	100.0
Duoc Hau Giang Pharmaceutical JSC	Vietnam	,000 VND 1,307,460,710	SMG	51.0
UPSA SAS	France	,000 EUR 852,103	SMG	100.0
UPSA Switzerland A.G.	Switzerland	,000 CHF 100	SMG	100.0
UPSA Italy S.r.l.	Italia	,000 EUR 10	SMG	100.0
UPSA Belgium S.A.	Belgium	,000 EUR 62	SMG	100.0
(2) Equity accounting method				
Yomeishu Seizo Co., Ltd.	Tokyo, Japan	,000 Yen 1,650,000	SMG	24.0

SMG=Self-Medication operations PD=Prescription Pharmaceutical operations

*Ownership: including the portion of indirect ownership

** Shares were exchanged to become a subsidiary fully owned by Taisho Pharmaceutical Holdings Co., Ltd. on July 30, 2021

Prescription Pharmaceutical Operations: New Drug Development - Taisho Pharmaceutical

As of August 5, 2021

In Japan

Filed

Lusefi (Oral)

< Application	> Type2 diabetes
< Development	> In-house
< Description	> SGLT2 (Sodium-Glucose Cotransporter2) inhibitor
< Remarks	> Generic name: Luseogliflozin Hydrate Product name: Lusefi® Orally disintegrating film drug (drug form added)

TS-152 (Injection)

< Application	> Articular rheumatism against which existing therapies have insufficient efficacy
< Development	> In-license (Licensor: Ablynx)
< Description	> Anti-TNF(Tumor Necrosis Factor)-α antibody
< Remarks	> Generic name: Ozoralizumab

Phase 3

TS-071(Oral)

< Application	> Type2 diabetes (Pediatric)
< Development	> In-house
< Description	> SGLT2 (Sodium-Glucose Cotransporter2) inhibitor
< Remarks	> Generic name: Luseogliflozin Hydrate Product name: Lusefi®

Phase 2

TS-142 (Oral)

< Application	> Insomnia
< Development	> In-house

Phase 1

TS-172 (Oral)

< Application	> Hyperphosphatemia
< Development	> In-house

Prescription Pharmaceutical Operations: New Drug Development - Taisho Pharmaceutical

As of August 5, 2021

Overseas

Phase 2

TS-161 (Oral)

< Target disease > Depression

< In-house/Licensed-in > In-house

Phase 1

TS-134 (Oral)

< Target disease > Schizophrenia

< In-house/Licensed-in > In-house

TS-142 (Oral)

< Target disease > Insomnia

< In-house/Licensed-in > In-house

Launch of New Products

As of August 5, 2021

New Products Since FY2020 Earnings Announcement (May 14, 2021)

Self-Medication Operations

ALFE RICHGRACE

- < Description > A new product from the ALFE GRACE series, the product line for beauty to be realized from inside the body, for those who want to stay beautiful with dignity, regardless of age, and who want to be ever more brilliant as they get older. The best-grade formula in the series, containing a generous amount of proteoglycan, swallow nests, collagen derived from shark fin in addition to 5000 mg of collagen peptide that boasts the greatest content in the series.
- < Launch > May 2021

Lipovitan ICE SLURRY for Sports

- < Description > A new product in the Lipovitan for Sports series for the athletes who do sports hard and those who do exercise for keeping physical health. Contains sodium and potassium that are easily lost as sweat and other ingredients including citric acids necessary for energy generation, vitamin B₁, vitamin B₂, and vitamin B₆. The ice slurry form is convenient for ingesting nutrients and salt that tend to be used up during exercise in hot weather.
- < Launch > June 2021

Lipovitan JELLY

- < Description > Lipovitan Jelly , launched in April last year, has become a food with a functional claim. A jelly-form beverage in a pouch can be easily consumed, containing vitamin B₁, vitamin B₂, and vitamin B₆ in addition to 1000 mg citric acids for alleviating a temporary sensation of fatigue after light exercise in daily life.
- < Launch > June 2021

Taisho Kampo Stomach Medicine

- < Description > Taisho Kampo Stomach Medicine is the gastrointestinal drug with two Chinese medicine prescriptions, Anchusan and Shakuyaku-kanzo-to, combined. It was launched in 1978. The content per sachet for the granule type was decreased, and the tablets were downsized while the effectiveness has been retained. In addition, the package design was changed.
- < Launch > June 2021
-

Launch of New Products

As of August 5, 2021

New Products Since FY2020 Earnings Announcement (May 14, 2021)

Self-Medication Operations

Lipovitan D Featuring the Japan National Rugby Team 2021

- < Description > Two types of bottles are available: one in red and another in blue. The cherry-blossom emblem of the Japan national rugby union team appears at the center of the label, above which the catchphrase of Lipovitan D "Fight! Ippatsu! (knock out in English)" is printed. A ten-pack is a special package, the design of which was inspired by the jersey of the Japan national rugby union team.
- < Launch > June 2021

Lipovitan D Japanese professional baseball teams bottle

- < Description > The limited edition bottles have been released annually and are popular with professional baseball team fans and the general public since they were first launched in 2017. This year again, four bottles are newly available, designed using the mascots and logos of the teams.
- < Launch > June 2021

Pabron Mouthwash C

- < Description > A mildly mint-flavored mouthwash containing cetylpyridinium chloride hydrate, which sterilizes the mouth and throat, and dipotassium glycyrrhizinate, which has anti-inflammatory effects.
The large pump holds 470 mL content. Keep it at home or the office. It is easy to use: Just one push per wash.
- < Launch > June 2021

Lipovitan D Space Brothers Bottle 2

- < Description > Five types of designed bottles are available, featuring the wise sayings of characters and famous scenes from the popular manga *Uchu Kyodai (Space Brothers)*. The outer case (for 10 bottles) features a new image of *Uchu Kyodai* with Lipovitan D drawn by its author *Chuya Koyama*.
- < Launch > July 2021

Lipovitan JELLY for Long-Term Storage

- < Description > A package contains 100 g of jelly-form beverage corresponding to 200 kcal. The special technology* enables long-term storage of up to five years (66-month best before period after production). Free from 28 allergens. Free from caffeine. Supports nutrition and water intake for all consumers in a disaster or emergency. Meets demand for stockpiling for government, schools, businesses and homes.
*TOKINAX, the brand of the filling technology developed by ONETABLE Inc. The combination of the filling technology for long-term storage, film with four layers including aluminum, and the recipe control technology.
- < Launch > July 2021